KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Elanco Animal Health (ELAN) Research & Development (2017 - 2025)

Elanco Animal Health's Research & Development history spans 9 years, with the latest figure at $93.0 million for Q4 2025.

  • For Q4 2025, Research & Development rose 14.81% year-over-year to $93.0 million; the TTM value through Dec 2025 reached $368.0 million, up 6.98%, while the annual FY2025 figure was $368.0 million, 6.98% up from the prior year.
  • Research & Development for Q4 2025 was $93.0 million at Elanco Animal Health, up from $89.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $94.0 million in Q2 2021 and bottomed at $78.0 million in Q3 2022.
  • The 5-year median for Research & Development is $87.0 million (2024), against an average of $86.4 million.
  • The largest YoY upside for Research & Development was 58.25% in 2021 against a maximum downside of 20.0% in 2021.
  • A 5-year view of Research & Development shows it stood at $92.0 million in 2021, then fell by 13.04% to $80.0 million in 2022, then decreased by 1.25% to $79.0 million in 2023, then rose by 2.53% to $81.0 million in 2024, then grew by 14.81% to $93.0 million in 2025.
  • Per Business Quant, the three most recent readings for ELAN's Research & Development are $93.0 million (Q4 2025), $89.0 million (Q3 2025), and $92.0 million (Q2 2025).